Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07374029 · ClinicalTrials.gov registry record · Phase 1
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
A Phase 1 study, sponsored by David Avigan.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT07374029 is a Phase 1 study that is actively recruiting participants, run by David Avigan. The registered enrollment target is 30 participants.
The verdict
NCT07374029, a Phase 1 study, is actively recruiting participants, sponsored by David Avigan.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of this research study is to test if the combination of a new T cell therapy (dendritic cell (DC) / acute myeloid leukemia (AML) primed T cells), vaccine (DC/AML fusion vaccine) and standard of care decitabine and venetoclax is feasible and safe and effective for treatment of acute myeloid leukemia (AML). The names of the study drugs involved in this study are: * DC/AML fusion vaccine (immune cell vaccine) * Granulocyte-macrophage colony-stimulating factor (GM-CSF) (a type of growth factor or hormone) * DC/AML Primed T cells (immune cells) * Decitabine (a type of chemotherapy drug) * Venetoclax (a type of antineoplastic agent)
Interventions
- DRUG Venetoclax
- DRUG Decitabine
- DRUG GM-CSF
- BIOLOGICAL DC/AML Fusion Vaccine
- BIOLOGICAL T-Cell Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-02-12 |
| Est. Completion | 2030-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07374029
The ClinicalTrials.gov registry entry for NCT07374029 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David Avigan, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Venetoclax is the first listed.
NCT07374029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07374029 about?
NCT07374029 is a clinical study titled "Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML". The goal of this research study is to test if the combination of a new T cell therapy (dendritic cell (DC) / acute myeloid leukemia (AML) primed T cells), vaccine (DC/AML fusion vaccine) and standard of care decitabine and venetoclax is feasible and safe and effective for treatment of acute myeloid ...
What is the current status of trial NCT07374029?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-02-12. Estimated completion is 2030-10-01.
What interventions are being tested in trial NCT07374029?
The interventions under investigation include: Venetoclax (DRUG), Decitabine (DRUG), GM-CSF (DRUG), DC/AML Fusion Vaccine (BIOLOGICAL), T-Cell Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT07374029?
This trial is sponsored by David Avigan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.